Institute of Gastrosciences and Liver, Apollo Gleneagles Hospitals, 58 Canal Circular Road, Kolkata, 700 054, India.
Indian J Gastroenterol. 2020 Aug;39(4):321-330. doi: 10.1007/s12664-020-01069-0. Epub 2020 Aug 26.
The disease burden of inflammatory bowel diseases (IBD) in India is estimated to be one of the highest in the world in the near future. Patients with IBD, particularly those on immunosuppressive therapy, are at increased risk for developing vaccine-preventable illnesses. Adult vaccination policy and vaccination in patients with IBD are presently being at a very low level in India. This review discusses in detail the need for vaccination, levels of immunosuppression, a brief account of live and inactivated vaccines, available vaccines, and their utility in patients with IBD, with a special focus on recent recommendations.
在不远的将来,印度炎症性肠病(IBD)的疾病负担预计将成为全球最高之一。IBD 患者,特别是接受免疫抑制治疗的患者,发生疫苗可预防疾病的风险增加。目前,印度的成人疫苗接种政策和 IBD 患者的疫苗接种水平都非常低。这篇综述详细讨论了接种疫苗的必要性、免疫抑制程度、活疫苗和灭活疫苗的简要说明、可用疫苗及其在 IBD 患者中的应用,特别关注了最近的建议。